

**REMARKS**

Applicants hereby elect **Group II**, namely **Claims 14, 27, 28, 33, 46-47, 52, 65-66, 71, 84-85, 90, 103-104, 109, 122-123, 128, 141-142, 147, 160-161, 166, 177-178, 183, 196-197 and 202**, drawn to isolated polypeptides.

With respect to the amino acid sequence species requirements, Applicants select the amino acid sequence of Met 934, SEQ ID No.: 1. Of the above claims, claim 14 is readable on the elected species and is currently amended herewith for the sake of clarity only.

Applicants respectfully urge that claim 8, also drawn to isolated polypeptides, was inadvertently included in the isolated polynucleotide claims of Group I, but should have been included in the Group II isolated polypeptide claims. Of these, claim 8 is directed to the elected species SEQ ID No.: 1 and should be examined along with claim 14. New claims 208 and 209 have been added, drawn to polynucleotides coding for the polypeptides of claims 8 and 14, respectively.

Applicants reserve the right to file, at a later date, additional divisional applications claiming priority from the present application which are directed to the non-elected Group.

An Office Action on the merits of claims 8, 14, 208, and 209 is respectively requested.

Respectfully submitted,



Martin D. Moynihan  
Registration No. 40,338

Date: May 30, 2006

**Enclosures:**

Petition for Extension (3 months);  
Additional Claims Transmittal Sheet